#USA #New York #Securities Fraud #Pomerantz LLP #Cellectis S.A.

Pomerantz Law Firm Investigates Cellectis S.A.

Recently, Pomerantz LLP began a scrutiny of claims from investors of Cellectis S.A., a biotechnology firm listed on NASDAQ under the ticker CLLS. The investigation stems from concerns that the company and some of its executives may have participated in securities fraud or engaged in other unethical business practices which misled investors.

On September 14, 2026, Cellectis made a significant announcement that shook investor confidence. The company revealed its shift in focus from CAR-T cell therapies to in vivo gene editing therapies. The two treatments, HEAL-101 and HEAL-201, received priority, while Cellectis decided to halt the development of its CAR-T cell therapies, specifically lasme-cel and eti-cel. In the conference call that accompanied this news, the Chief Medical Officer, Adrian Kilcoyne, pointed out the difficult financial situation faced by Cellectis, stating, "Cellectis is not able [to] finance [Eti-cel and Lasme-cel] given the time lines that we have and the limited cash resources that we have." Such remarks raised flags regarding the company's fiscal health and strategic management.

The market reacted sharply to this revelation, with Cellectis's American Depositary Receipt (ADR) suffering a staggering decline. On the day of the announcement, the ADR price plummeted by $1.27, marking a 40.97% drop, bringing the closing price down to $1.83. This significant downturn in stock value provoked alarm among shareholders and potential investors, prompting the inquiry by Pomerantz LLP.

Pomerantz LLP is renowned for its focus on corporate, securities, and antitrust class actions. Established over 85 years ago by Abraham L. Pomerantz, often referred to as the founder of the securities class action field, the firm has a deep commitment to advocating for victims of securities fraud and corporate wrongdoing. This reputation further solidifies the importance of the current investigation as they prepare to represent those affected by the recent downturn.

In light of the investigation, Pomerantz LLP is urging investors who engaged with Cellectis to come forward. Interested individuals are encouraged to reach out to Danielle Peyton at the firm for more information about participating in the class action.

For those closely monitoring the developments surrounding Cellectis, the next steps in this investigation will be pivotal as they could unveil deeper implications for the company's future and hold its leadership accountable for any potential misconduct. As the situation unfolds, investors are advised to remain vigilant and informed about their stakes in the company.